Want to see CALC full AI Analyst Report?
CALC Stock Chart & Stats
$0.59
-$0.06(-7.45%)
At close: 4:00 PM EDT
$0.59
-$0.06(-7.45%)
Day’s Range― - ―
52-Week Range$1.58 - $36.00
Previous Close$0.71
Volume201.26K
Average Volume (3M)90.42K
Market Cap
$11.06M
Enterprise Value$8.20
Total Cash (Recent Filing)$18.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Nov 18, 2026EPS Estimate
-1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.90
Shares Outstanding6,828,292
10 Day Avg. Volume61,074
30 Day Avg. Volume90,419
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside1425.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe absence of debt reduces near-term leverage and interest-burden risk, giving CalciMedica greater flexibility while it funds clinical development. Positive equity also provides a stronger base than prior periods with negative equity, although continued losses remain a constraint.
Focused CRAC PlatformCalciMedica has a clearly defined therapeutic platform built around CRAC channel modulation and oral small-molecule candidates. A focused mechanism can support efficient research prioritization and potential expansion across inflammatory and immunologic diseases if clinical results validate the approach.
Nasdaq Compliance RestoredRestored Nasdaq compliance removes an immediate listing obstacle and supports continued access to public capital markets, employees, and institutional counterparties. This improves operating stability over the coming months, even though it does not resolve the company’s financing needs.
Bears Say
No Commercial RevenueThe absence of revenue means CalciMedica has not yet demonstrated commercial demand or a self-funding business model. Persistent operating losses leave future progress dependent on successful development, regulatory execution, and eventual product commercialization rather than established recurring sales.
Persistent Cash BurnContinued cash consumption reduces the time available to advance programs without additional financing. Because free cash flow remains firmly negative despite improvement from 2025, CalciMedica must either raise capital, reduce spending, or generate revenue to sustain development activities.
Equity Financing And DilutionThe ATM program provides liquidity flexibility but also underscores dependence on equity financing while operations generate no revenue. Future stock sales can dilute existing ownership and may pressure capital allocation, particularly if clinical spending continues before internally generated cash flow emerges.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $1.58 and its highest was $36.00 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $11.06M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is Nov 18, 2026 which is in 47 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on Aug 11, 2026. The company reported -$2.25 earnings per share for the quarter, missing the consensus estimate of -$1.425 by -$0.825.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -1.28.
How many shares outstanding does CalciMedica have?
CalciMedica has 6,828,292 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of -$2.25 in its last earnings report, missing expectations of -$1.425. Following the earnings report the stock price went down -0.182%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
CALC Stock 12 Month Forecast
Average Price Target
$9.00
▲(1425.42% Upside)
Technical Analysis
Ownership Overview
35.37% Insiders
0.73% Mutual Funds
26.44% Other Institutional Investors
37.20% Public Companies and
Individual Investors